Literature DB >> 15782070

Mucinous ovarian tumors of Mullerian-type: an analysis of 17 cases including borderline tumors and intraepithelial, microinvasive, and invasive carcinomas.

Valérie Dubé1, Michel Roy, Marie Plante, Marie-Claude Renaud, Bernard Têtu.   

Abstract

Mullerian-type mucinous tumors (MMTs) of the ovary are characterized by a papillary architecture similar to that of serous tumors and a content of endocervical-like mucinous epithelium. The latter may be admixed with other mullerian-type epithelia, including those of serous, endometrioid, and squamous types, and indifferent eosinophilic epithelial cells. We analyzed 17 MMTs, including 12 borderline tumors, 2 intraepithelial carcinomas, 2 microinvasive carcinomas, and 1 invasive carcinoma. Fourteen of 16 tumors (88%) with available staging were stage I; the remaining two cases (both borderline) were stage IIa and IIIc. Endometriosis was identified in eight cases (47%). Only two patients (12%) had bilateral tumors, a frequency of bilaterality lower than in previous studies. Five patients (31%) had conservative treatment consisting of a cystectomy or unilateral salpingo-oophorectomy. All patients had a favorable outcome, with no recurrences or disease-related deaths, regardless of the presence of high mitotic index, intraepithelial carcinoma, microinvasion, bilaterality, conservative treatment, or advanced stage. This indolent behavior of MMTs is similar to that previously reported, but additional cases of invasive carcinomas in this category are needed to better define their outcome.

Entities:  

Mesh:

Year:  2005        PMID: 15782070     DOI: 10.1097/01.pgp.0000152024.37482.63

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  7 in total

1.  Ovarian Seromucinous Borderline Tumors Are Histologically Different from Mucinous Borderline Tumors.

Authors:  Taira Hada; Morikazu Miyamoto; Hiroki Ishibashi; Haruka Kawauchi; Hiroaki Soyama; Hiroko Matsuura; Takahiro Sakamoto; Soichiro Kakimoto; Tadashi Aoyama; Hideki Iwahashi; Rie Suzuki; Hitoshi Tsuda; Masashi Takano
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 2.  Diagnosis, treatment, and follow-up of borderline ovarian tumors.

Authors:  Daniela Fischerova; Michal Zikan; Pavel Dundr; David Cibula
Journal:  Oncologist       Date:  2012-09-28

3.  Somatic mutations of PPP2R1A in ovarian and uterine carcinomas.

Authors:  Ie-Ming Shih; Pradeep K Panuganti; Kuan-Tin Kuo; Tsui-Lien Mao; Elisabetta Kuhn; Sian Jones; Victor E Velculescu; Robert J Kurman; Tian-Li Wang
Journal:  Am J Pathol       Date:  2011-02-26       Impact factor: 4.307

4.  Mutation Profiles of Ovarian Seromucinous Borderline Tumors in Japanese Patients.

Authors:  Hiroki Sasamori; Kentaro Nakayama; Sultana Razia; Hitomi Yamashita; Tomoka Ishibashi; Masako Ishikawa; Seiya Sato; Satoru Nakayama; Yoshiro Otsuki; Ritsuto Fujiwaki; Noriyoshi Ishikawa; Satoru Kyo
Journal:  Curr Oncol       Date:  2022-05-18       Impact factor: 3.109

5.  Ovarian Seromucinous Borderline Tumor and Clear Cell Carcinoma: An Unusual Combination.

Authors:  Eriko Nakamura; Yuichiro Sato; Sayaka Moriguchi; Atsushi Yamashita; Takashi Higo; Yujiro Asada
Journal:  Case Rep Obstet Gynecol       Date:  2015-05-13

6.  Anaplastic carcinoma in ovarian seromucinous cystic tumor of borderline malignancy.

Authors:  Toshiyuki Okumura; Etuo Muronosono; Masahiko Tsubuku; Yasuhisa Terao; Satoru Takeda; Masanori Maruyama
Journal:  J Ovarian Res       Date:  2018-09-03       Impact factor: 4.234

Review 7.  Ovarian Seromucinous Tumors: Pathogenesis, Morphologic Spectrum, and Clinical Issues.

Authors:  Michiko Nagamine; Yoshiki Mikami
Journal:  Diagnostics (Basel)       Date:  2020-01-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.